This activity was funded by Alnylam Pharmaceuticals. The medical content was developed independently by M3 and Professor Violaine Planté-Bordeneuve.
Cardiac imaging in ATTR amyloidosis
Identifying ATTR-CM: are we doing enough?
Tafamidis treatment in ATTRv-PN: clinical and real-world evidence
HELIOS-A: positive 9-month results with an investigational RNAi for patients with hATTR amyloidosis and polyneuropathy
Patisiran in hATTR amyloidosis: beyond the APOLLO phase III study
Long-term efficacy and safety of an antisense oligonucleotide inhibitor in hATTR amyloidosis with polyneuropathy
Tafamidis treatment in patients with ATTR-CM
The future landscape of ATTR-CM treatment
A single-dose alternative to gene silencing therapies in hATTR? Results from the first in-human demonstration of CRISPR-based gene editing therapy
What is the potential of antisense drugs for rare neurological disease?
Key factors for the diagnosis and management of ATTR amyloidosis
Neurofilament light chain (NfL): a potential biomarker of disease progression and treatment response?
What can we learn from patient-reported outcomes in hATTR amyloidosis?
Outcomes with patisiran in patients with hATTR amyloidosis with polyneuropathy post-orthotopic liver transplantation
Why early intervention matters in cardiac hATTR amyloidosis
Top image: Eraxion
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.